A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Recruiting

Phase 1

BGB-B2033 & TislelizumabA Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Sponsor:

BeOne Medicines

Code:

NCT06427941

Conditions

Metastatic Hepatocellular Carcinoma

Local Advanced Hepatocellular Carcinoma

Alpha-fetoprotein (AFP)-Producing Gastric Cancer

Extragonadal Yolk Sac Tumors

Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BGB-B2033

Tislelizumab

Bevacizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-30. This information was provided to ClinicalTrials.gov by BeOne Medicines on 2026-03-18.